Japan's Kyowa Kirin reorganizes quality responsibilities 

Japan's Kyowa Kirin has set in motion changes to its quality assurance. (Kyowa Kirin)

Japan’s Kyowa Kirin, which recently won approval in the U.S. of a drug for Parkinson’s disease, says it is putting quality assurance and pharmacovigilance front and center. 

Under a company reorganization that takes effect Jan. 1, the company has created quality and pharmacovigilance divisions that will report directly to the CEO, Kyowa Kirin announced (PDF) today. 

RELATED: Spurned by FDA a decade ago, Kyowa Kirin wins nod for Parkinson's drug

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

As part of the reorg, it is establishing quality assurance and regulatory audit departments that will be part of the quality division. It said the changes were made to clarify roles and responsibilities and to pursue maintenance and improve the quality of the drugs it makes.

The changes come three months after Kyowa Kirin won FDA approval of Nourianz, which had been rejected by the FDA more than a decade ago. The drug has been sold in Japan since 2013 but was turned away by the FDA in 2008 over concerns about its efficacy. 

RELATED: Japanese API maker Kyowa Hakko Bio admits manipulating testing data

Last year, another unit of Kirin Holdings, Kyowa Hakko Bio, had a plant in Yamaguchi, Japan, slapped with a warning letter after managers acknowledged workers manipulated data to get passing results when out-of-specification results appeared during testing. 

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.